Scarica l'app Stockscreener
118.00
0.80%
0.94
Pre-mercato:
119.99
1.99
+1.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$117.06
Aprire:
$117.75
Volume 24 ore:
633.67K
Relative Volume:
0.71
Capitalizzazione di mercato:
$11.66B
Reddito:
$1.64B
Utile/perdita netta:
$121.85M
Rapporto P/E:
76.62
EPS:
1.54
Flusso di cassa netto:
$-480.40M
1 W Prestazione:
-5.44%
1M Prestazione:
-6.17%
6M Prestazione:
-19.67%
1 anno Prestazione:
+0.81%
Intervallo 1D:
$115.61
$118.45
Intervallo di 1 settimana:
$114.42
$127.91
Portata 52W:
$102.16
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Confronta SRPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
118.00 | 11.66B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey
Smith Salley Wealth Management Invests $889,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
FY2024 Earnings Forecast for SRPT Issued By HC Wainwright - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright - MarketBeat
HC Wainwright Issues Optimistic Forecast for SRPT Earnings - MarketBeat
Sarepta preliminary Q4 revenue beats, but full year just misses - MSN
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics - Benzinga
J&J files a potential blockbuster; Lykos shakes up its board - BioPharma Dive
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Harbor Capital Advisors Inc. Acquires 427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | Company Business News - Mint
Sarepta Bullish After Another Big Beat For Elevidys - News & Insights
Sarepta Therapeutics (NASDAQ:SRPT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat - BioSpace
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Sarepta exceeds revenue forecasts, maintains 2025 guidance - Investing.com India
Sarepta Therapeutics Tops 2024 Net Product Revenue Guidance - MarketWatch
Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue - StreetInsider.com
Sarepta Therapeutics Smashes Revenue Targets as ELEVIDYS Sales Surge 112% in Q4 2024 - StockTitan
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Nordea Investment Management AB - MarketBeat
Zacks Research Issues Pessimistic Forecast for SRPT Earnings - MarketBeat
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock poised for growth - Investing.com Canada
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga
Nippon Shinyaku Hit With Royalty Tab After $115 Million Verdict - Bloomberg Law
SRPT February 28th Options Begin Trading - Nasdaq
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? - MSN
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference - Benzinga
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $178.71 - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
LABU, NTRA, INCY, SRPT: Large Inflows Detected at ETF - Nasdaq
Sarepta Therapeutics Grants 10,660 RSUs to New Employees in Strategic Talent Acquisition Move - StockTitan
Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Duchenne Muscular Dystrophy Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeuti - Barchart
Exploring High Growth Tech Stocks in the US December 2024 - Simply Wall St
Page 4 | SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView
SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView
Principal Financial Group Inc. Sells 95,974 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? - Insider Monkey
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):